Prof.Dr Jean Pierre MAJORAL
Laboratoire Chimie de Coordination, CNRS-UPR 8241
Toulouse
jean-pierre.majoral@lcc-toulouse.fr

Title : Phosphorus Dendrimers as nanocarriers or drugs active per se
Selected recent advances

Abstract :

Dendrimers – nano-sized symmetrical macromolecules with nearly monodisperse structures – are used for many applications in different fields due to the fine tuning of their physicochemical and biological properties.
Among the families of dendrimers, phosphorus dendrimers were found one of the most efficient nanodevices notably in nanomedicine both as nanocarriers or as drugs active per se. For exemple they were used as antiprions agents, stimulators of human natural killer (NK) cells, as anti-inflammatory compounds depending on the type of their terminal: neutral, anionic, cationic or metalated (Cu, Au, Ti, Ru, Zr, etc) groups or against Alzheimer and Parkinson diseases. Outstandingly, modification of the dendrimer terminal groups effectively changes the therapeutic domains, all these results allowing us to propose a novator concept of dendrimer space for innovative nanomedicine Phosphorus dendrimers are also used in a variety of other fields ranging from nanosciences to catalysis or for the formation of hybrid organic inorganic materials and unprecedented bioplastics.

Novel multistep synthesis in high yield of original stable and not sensitive to hydrolysis of a variety of neutral, cationic or anionic phosphorus dendrimers will be reported. Several recent applications will be illustrated in different domains using these phosphorus dendrimers as antituberculosis, anticancers, antimicrobial, or anti inflammatory compounds. Their contribution in the DNA-based multiplexing technology for accurate diagnosis of pathogens in the fields of respiratory diseases, sexual diseases diagnosis will be presented

Biography :

Dr. Jean-Pierre Majoral works on the design and development of first-in-class dendrimers for therapeutic applications, material sciences, and catalysis. His research aims at opening new directions in nanomedicine to fight difficult diseases such as tuberculosis and cancers.
Dr. Jean-Pierre Majoral obtained his BSc, followed by a PhD, from the University of Paul Sabatier (UPS), Toulouse, France in 1973. He subsequently spent a year at University of East Anglia, Norwich (UK) as a Post-doctoral Fellow. He started his academic career at Laboratoire de Chimie Physique at the UPS, Toulouse (France), in 1972 as Attaché de Recherche, then moved to the Laboratoire de Chimie de Coordination, CNRS, Toulouse, France in 1988, and arose to the status of Directeur de Recherche Classe Exceptionnelle CNRS in 1997. He was appointed as Directeur de Recherche CNRS Emerite in 2006, and holds that position currently. He was the Vice-Director of Laboratoire de Chimie de Coordination, Toulouse, France from 1998–2002, and Editor-in-Chief of New Journal of Chemistry from 2005–2009. He is also the co-founder of two companies Dendris (2009), and Biodendrimer International (2011).